Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients

被引:197
作者
Gandhi, Maher K.
Lambley, Eleanore
Duraiswamy, Jaikumar
Dua, Ujjwal
Smith, Corey
Elliott, Suzanne
Gill, Devinder
Marlton, Paula
Seymour, John
Khanna, Rajiv
机构
[1] Queensland Inst Med Res, Bancroft Ctr, Tumor Immunol Lab, Div Infect Dis & Immunol, Brisbane, Qld 4029, Australia
[2] Univ Melbourne, Peter MacCallum Canc Ctr, Haematol Serv, Melbourne, Vic, Australia
[3] Princess Alexandra Hosp, Dept Haematol, Brisbane, Qld 4102, Australia
关键词
EPSTEIN-BARR-VIRUS; REED-STERNBERG CELLS; PERIPHERAL-BLOOD; IN-VITRO; DISEASE; RESPONSES; EPITOPES; PROTEIN; LINES; ACTIVATION;
D O I
10.1182/blood-2006-04-015164
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In Hodgkin lymphoma (HL), the malignant Hodgkin Reed-Sternberg (HRS) cells constitute only 0.5% of 10% of the diseased tissue. The surrounding cellular infiltrate is enriched with T cells that are hypothesized to modulate antitumor immunity. We show that a marker of regulatory T cells, LAG-3, is strongly expressed on infiltrating lymphocytes present in proximity to HRS cells. Circulating regulatory T cells (CD4(+) CD25(hi) CD45 ROhi, CD4(+) CTLA4(hi), and CD4(+) LAG-3(hi)) were elevated in HL patients with active disease when compared with remission. Longitudinal profiling of EBV-specific CD8(+) T-cell responses in 94 HL patients revealed a selective loss of interferon-gamma expression by CD8(+) T cells specific for latent membrane proteins 1 and 2 (LMP1/2), irrespective of EBV tissue status. Intratumoral LAG-3 expression was associated with EBV tissue positivity, whereas FOXP3 was linked with neither LAG-3 nor EBV tissue status. The level of LAG-3 and FOXP3 expression on the tumor-infiltrating lymphocytes was coincident with impairment of LMP1/2-specific T-cell function. In vitro pre-exposure of peripheral blood mono-nuclear cells to HRS cell line supernatant significantly increased the expansion of regulatory T cells and suppressed LMP-specific T-cell responses. Deletion of CD4(+) LAG-3(+) T cells enhanced LMP-specific reactivity. These findings indicate a pivotal role for regulatory T cells and LAG-3 in the suppression of EBV-specific cell-mediated immunity in HL.
引用
收藏
页码:2280 / 2289
页数:10
相关论文
共 55 条
[41]   CD25+ CD4+ regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4+ and CD8+ HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status [J].
Kinter, AL ;
Hennessey, M ;
Bell, A ;
Kern, S ;
Lin, Y ;
Daucher, M ;
Planta, M ;
McGlaughlin, M ;
Jackson, R ;
Ziegler, SE ;
Fauci, AS .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 200 (03) :331-343
[42]  
Lee SP, 1997, J IMMUNOL, V158, P3325
[43]   The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells [J].
Maçon-Lemaître, L ;
Triebel, F .
IMMUNOLOGY, 2005, 115 (02) :170-178
[44]   Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma [J].
Marshall, NA ;
Christie, LE ;
Munro, LR ;
Culligan, DJ ;
Johnston, PW ;
Barker, RN ;
Vickers, MA .
BLOOD, 2004, 103 (05) :1755-1762
[45]   Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1 [J].
Marshall, NA ;
Vickers, MA ;
Barker, RN .
JOURNAL OF IMMUNOLOGY, 2003, 170 (12) :6183-6189
[46]   A recombinant adenovirus expressing an Epstein-Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory in vitro [J].
Morgan, SM ;
Wilkinson, GWG ;
Floettmann, E ;
Blake, N ;
Rickinson, AB .
JOURNAL OF VIROLOGY, 1996, 70 (04) :2394-2402
[47]   Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes [J].
Pepperl, S ;
Benninger-Döring, G ;
Modrow, S ;
Wolf, H ;
Jilg, W .
JOURNAL OF VIROLOGY, 1998, 72 (11) :8644-8649
[48]   Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas [J].
Poppema, S ;
van den Berg, A .
SEMINARS IN CANCER BIOLOGY, 2000, 10 (05) :345-350
[49]   Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positiye relapsed Hodgkin's disease [J].
Roskrow, MA ;
Suzuki, N ;
Gan, YJ ;
Sixbey, JW ;
Ng, CYC ;
Kimbrough, S ;
Hudson, M ;
Brenner, MK ;
Heslop, HE ;
Rooney, CM .
BLOOD, 1998, 91 (08) :2925-2934
[50]   T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis [J].
Scotet, E ;
DavidAmeline, J ;
Peyrat, MA ;
MoreauAubry, A ;
Pinczon, D ;
Lim, A ;
Even, J ;
Semana, G ;
Berthelot, JM ;
Breathnach, R ;
Bonneville, M ;
Houssaint, E .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (05) :1791-1800